A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.
BACKGROUND
Effective and safe products are needed for long-term management of scalp psoriasis. This study investigated the long-term safety and efficacy of a two-compound formulation (calcipotriol 50 microg/g plus betamethasone dipropionate 0.5 mg/g) for scalp psoriasis.


METHODS
In this 52-week, international, double-blind study, 869 patients with moderate-to-severe scalp psoriasis were randomized to either a two-compound scalp formulation (n = 429) or calcipotriol (n = 440).


RESULTS
Adverse drug reactions were less frequent in the two-compound group compared with the calcipotriol group (17.2 vs. 29.5%; p < 0.001). Incidences of adverse events possibly associated with long-term corticosteroid use were low in both the two-compound (2.6%) and the calcipotriol (3.0%) groups. Disease was satisfactorily controlled in 92.3% of visits in the two-compound group versus 80.0% in the calcipotriol group (p < 0.001).


CONCLUSIONS
The two-compound scalp formulation demonstrated a high level of safety and efficacy in long-term management of scalp psoriasis.
Luger
T A
TA
Department of Dermatology, University Clinic Münster, Münster, Germany. luger@uni-muenster.de
Cambazard
F
F
Larsen
F G
FG
Bourcier
M
M
Gupta
G
G
Clonier
F
F
Kidson
P
P
Shear
N H
NH
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001623:Betamethasone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002117:Calcitriol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002170:Canada; D003718:Denmark; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005602:France; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D014677:Pharmaceutical Vehicles; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D012535:Scalp; D012720:Severity of Illness Index; D016896:Treatment Outcome; D006113:United Kingdom
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D009824:Ointments; D014677:Pharmaceutical Vehicles; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol
Br J Dermatol. 2006 Jun;154(6):1155-60
16704648
Dermatology. 1998;197(4):326-34
9873169
Br J Dermatol. 1998 Oct;139(4):649-54
9892908
Arch Dermatol. 2004 Apr;140(4):408-14
15096368
J Am Acad Dermatol. 2008 Sep;59(3):455-63
18694678
Dermatology. 2008;217(2):107-13
18463448
BMJ. 2003 Jun 21;326(7403):1367
12816824
Arch Dermatol Res. 1990;282(3):164-7
2164359
Cutis. 1992 Jun;49(6):396-400
1628504
J Eur Acad Dermatol Venereol. 2006 Jan;20(1):39-44
16405606
Br J Dermatol. 2009 Jan;160(1):170-6
19067709
Expert Opin Pharmacother. 2006 Apr;7(5):597-606
16553575
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii83-6
15708945
J Dermatolog Treat. 2006;17(2):90-5
16766333
Am J Clin Dermatol. 2001;2(3):159-65
11705093
Acta Derm Venereol. 1978;58(2):145-8
76394
J Dermatolog Treat. 2007;18(2):84-7
17520464
Br J Dermatol. 2003 Jan;148(1):134-8
12534607
Dermatology. 2000;200(4):292-8
10894958
Am J Clin Dermatol. 2003;4(4):221-4
12680800
Eur J Dermatol. 2000 Apr-May;10(3):199-204
10725818